Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
Conventional in vitro methods were used to determine the postantibiotic effects (PAEs), sub-MIC effects (SMEs), and postantibiotic sub-MIC effects (PA-SMEs) of garenoxacin for a range of organisms. The mean PAEs of garenoxacin for pneumococci, staphylococci, and enterococci were 0.3 to 2.2 h. For Escherichia coli and Pseudomonas aeruginosa, the PAEs were 0.9 to 1.6 h. The mean PA-SMEs (0.4 times the MIC) for pneumococci, staphylococci, and enterococci were 3.0 to >10 h, 1.8 to >10.7 h, and 5.8 h, respectively, while those for E. coli and P. aeruginosa were 7.6 and 4.4 h, respectively.
Pankuch
G A
GA
Department of Pathology, Hershey Medical Center, Pennsylvania 17033, USA.
Jacobs
M R
MR
Appelbaum
P C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D003470:Culture Media; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D007211:Indoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D003470:Culture Media; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin